Retatrutide: The next weight loss peptide everyone is waiting for
Ozempic made headlines. Mounjaro pushed the numbers higher. But there’s a third peptide in the pipeline that’s showing results neither of them can touch.
Retatrutide. A triple-hormone-receptor agonist. And the Phase 2 trial data is making the entire weight loss industry nervous.
What makes retatrutide different
Ozempic (semaglutide) targets one receptor: GLP-1. Mounjaro (tirzepatide) targets two: GLP-1 and GIP. Retatrutide targets three: GLP-1, GIP, and glucagon.
That third receptor — glucagon — is what changes everything.
Glucagon does something GLP-1 and GIP can’t: it directly increases energy expenditure. While GLP-1 suppresses appetite and GIP improves insulin sensitivity, glucagon forces your body to burn more calories at rest.
The result: Weight loss from three directions simultaneously. Less hunger. Better blood sugar. More calories burned. All at once.
The numbers from the Phase 2 trial
The Phase 2 trial, published in the New England Journal of Medicine, tested retatrutide in adults with obesity or overweight [1]. Here’s what they found after 48 weeks:
- 1mg dose: ~7.2% body weight loss
- 4mg dose: ~12.9% body weight loss
- 8mg dose: ~17.5% body weight loss
- 12mg dose: ~24.2% body weight loss
For context:
- Ozempic at maximum dose: ~15% weight loss
- Mounjaro at maximum dose: ~22.5% weight loss
- Retatrutide at 12mg: ~24.2% weight loss
And the weight was still coming off at 48 weeks. The curve hadn’t flattened. This suggests the total weight loss potential is even higher with longer treatment.
A network meta-analysis comparing seven GLP-1 receptor agonists and polyagonists confirmed that triple-receptor agonists like retatrutide showed superior weight loss efficacy compared to single or dual-receptor approaches [2].
Why women should pay attention
Weight loss after 40 is different. Estrogen decline changes how your body stores fat, processes insulin, and maintains muscle mass. The standard “eat less, move more” approach hits a wall because your hormones are actively working against you.
Retatrutide’s triple-receptor mechanism addresses this directly:
GLP-1: Reduces appetite and slows gastric emptying. You eat less without feeling deprived.
GIP: Improves insulin sensitivity. This is critical for women after 40 because estrogen decline worsens insulin resistance. Better insulin sensitivity means less visceral fat storage.
Glucagon: Increases energy expenditure. This is the one that matters most for women because it counteracts the metabolic slowdown that happens after menopause.
The lean mass question: One of the concerns with any weight loss medication is muscle loss. A review in Metabolism highlighted that emerging pharmacotherapies need to focus on fat reduction while preserving lean mass [3]. Retatrutide’s glucagon component may help with this, but more data is needed from the Phase 3 trials.
Side effects
Like all GLP-1 medications, retatrutide has gastrointestinal side effects:
- Nausea — most common, usually improves over time
- Diarrhea — reported in early weeks
- Vomiting — less common, dose-dependent
- Constipation — can occur as the body adjusts
The side effect profile is similar to semaglutide and tirzepatide. Most are manageable with gradual dose escalation.
Important: These are prescription medications being studied in clinical trials. Retatrutide is NOT available to the public yet. The Phase 3 trials are ongoing. FDA approval is expected around 2026-2027.
The timeline
- 2023: Phase 2 trial published in NEJM
- 2024-2025: Phase 3 trials ongoing (TRIUMPH program)
- 2026-2027: Expected FDA submission
- 2027-2028: Potential availability
Eli Lilly is developing retatrutide. They’re the same company behind Mounjaro, so they know how to bring a weight loss drug to market.
What to do now
Don’t wait for retatrutide to start your health journey. The best time to optimize your metabolic health is now — before you need medication.
What actually works right now:
- Resistance training (preserves muscle, improves insulin sensitivity)
- Adequate protein (1.2-1.6g per kg body weight)
- Sleep optimization (poor sleep wrecks insulin sensitivity)
- Stress management (cortisol drives visceral fat storage)
If you’re considering GLP-1 medications now:
- Talk to your doctor about semaglutide or tirzepatide
- These are available now and work well
- Retatrutide is years away from availability
The bottom line
Retatrutide is the most promising weight loss medication in development. The triple-receptor approach produces weight loss numbers that surpass everything currently available. But it’s not available yet.
The Phase 3 trials will tell us more about long-term safety, muscle preservation, and real-world effectiveness. Until then, the best investment you can make is in your metabolic health through training, nutrition, and sleep.
References
Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. https://pubmed.ncbi.nlm.nih.gov/37366315/
Xie Z, Yang X, Lin Y, et al. Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials. Metabolism. 2024;163:156084. https://pubmed.ncbi.nlm.nih.gov/39305981/
Stefanakis K, et al. The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health. Metabolism. 2024. https://pubmed.ncbi.nlm.nih.gov/39481534/
This post contains affiliate links. If you purchase through these links, I may earn a small commission at no extra cost to you.
Coming soon
- Cold exposure, sauna, breathwork — what actually does something
- The supplement stack that actually helps with perimenopause
- Why your iron levels matter more than you think